Previous 10 | Next 10 |
AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC. PR Newswire NEW YORK , April 27, 2022 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announc...
Genetic testing company Fulgent Genetics (NASDAQ: FLGT) has had a wild ride over the past few years. At the beginning of the pandemic, Fulgent experienced parabolic revenue growth when it was able to pivot from its core, next-generation sequencing (NGS) business to produce COVID...
Fulgent Genetics (NASDAQ:FLGT) to acquire Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners. Total purchase price of ~$170M, closing expected in Q2. For Q1, anticipates total revenue to be ~$300...
Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent’s rapidly expanding genomic testing footprint Preliminary first quar...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...
Fulgent Genetics reported a better-than-expected FQ4 card. But, it could get much more challenging from FY22. Nonetheless, the company authorized a significant $250M stock repurchase program in early March. We discuss why FLGT stock remains a Buy. For further details see: ...
Since 2020, many investors have developed exceptionally high expectations for the stock market because of the jaw-dropping performances of some companies. Fulgent Genetics (NASDAQ: FLGT) , for example, gave investors over 763% returns from the start of 2020 to March 2021. Other stoc...
Fulgent Genetics is experiencing significant topline growth because of the COVID-19 testing services; The company’s core business revenue also grew by almost 3 times, and the diluted EPS doubled Year-on-Year; The emergence of the Omicron variant and Fulgent’s progres...
Fulgent Genetics (NASDAQ:FLGT) is +4.31% pre-market after announcing a share repurchase program under which it may buyback $250M of its common stock. The program will be funded using Fulgent's working capital. The genetic testing company had ~30.3M shares of common stock outstanding...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that its Board of Directors...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...